Immune checkpoint inhibitors (ICIs), particularly those targeting programmed death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), such as nivolumab and ipilimumab, have improved clinical outcomes and are now first-line treatments for ccRCC [6,7,8]. The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.